Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer

DF3/MUC1跨膜蛋白在人乳腺癌细胞表面高水平异常表达。MUC1过表达在乳腺癌中的功能意义尚不清楚。MUC1的细胞质结构域与catenin家族的信号蛋白，β - catenin，血小板红蛋白和p120ctn相关，这一发现获得了一些见解。β -连环蛋白在细胞膜上与E-钙粘蛋白相互作用，在细胞质中与大肠腺瘤性息肉病（APC）蛋白相互作用，在细胞核中与Tcf/LEF-1作为转录辅激活因子相互作用。-连环蛋白信号的失调与多种人类肿瘤的发展有关。MUC1抑制β -连环蛋白与e -钙粘蛋白的结合，从而破坏粘附体连接，这是与肿瘤进展相关的事件。MUC1与表皮生长因子受体（EGFR）、ErbB2 （HER2/neu）以及相关的ErbB3和ErbB4受体酪氨酸激酶相关。通过激活EGFR或c-Src酪氨酸激酶，MUC1细胞质域的磷酸化增加了MUC1和β -连环蛋白之间的相互作用。相比之下，糖原合成酶激酶3 β (gsk3 β)磷酸化MUC1， Wnt信号通路的效应，下调MUC1和β -连环蛋白之间的相互作用。我们的假设是，作为乳腺癌细胞中过度表达的结果，MUM有助于i)通过EGFR和相关ErbB2-4受体的生长因子信号的失调，以及ii)细胞膜和细胞核中连环蛋白家族成员的功能障碍。拟议的研究将解决这一假设，以及MUC1是否也作为细胞表面受体在乳腺肿瘤的发展中起作用。具体目的是：1)明确MUC1与EGF受体相互作用的功能意义；2)确定MUC1是否与ErbB2及其他ErbB受体家族成员相互作用；3)明确MUC1对ErbB受体介导的连环蛋白在细胞膜和细胞核中的信号传导的影响；4)鉴定直接激活MUC1作为细胞表面受体的配体。

The DF3/MUC1 transmembrane protein is aberrantly expressed at high levels on the surface of human breast cancer cells. The functional significance of MUC1 overexpression in breast cancer is unknown. Certain insights have been derived from the finding the cytoplasmic domain of MUC1 associates with members of the catenin family of signaling proteins, beta- catenin, plakoglobin and p120ctn. Beta-catenin interacts with E- cadherin at the cell membrane, with the adenomatous polyposis coli (APC) Protein in the cytosol and with Tcf/LEF-1 as a transcriptional coactivator in the nucleus. Dysregulation of beta-catenin signaling has been associated with the development of diverse human tumors. MUC1 suppresses binding of beta-catenin to E-cadherin and thereby disrupts the adherens junction, an event associated with tumor progression. MUC1 associates with the epidermal growth factor receptor (EGFR), ErbB2 (HER2/neu) and the related ErbB3 and ErbB4 receptor tyrosine kinases. Phosphorylation of the MUC1 cytoplasmic domain by activation of EGFR or the c-Src tyrosine kinase increases the interaction between MUC1 and beta-catenin. By contrast, phosphorylation of MUC1 by glycogen synthase kinase 3beta (GSK3beta), an effector of the Wnt signaling pathway, downregulates the interaction between MUC1 and beta-catenin. Our hypothesis is that, as a consequence of overexpression in breast cancer cells, MUM contributes to i) dysregulation of growth factor signaling through EGFR and the related ErbB2-4 receptors and ii) dysfunction of catenin family members at the cell membrane and in the nucleus. The proposed studies will address this hypothesis and whether MUC1 also functions as a cell surface receptor in breast tumor development. The Specific Aims are: 1) To define the functional significance of the interaction between MUC1 and the EGF receptor, 2) To determine whether MUC1 interacts with ErbB2 and other members of the ErbB receptor family; 3) To define the effects of MUC1 on ErbB receptor-mediated signaling of catenins at the cell membrane and in the nucleus; and 4) To identify ligands that function in directly activating MUC1 as a cell surface receptor.